Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from VRBPAC

One Historic Week for Flu: Generic Xofluza Approved June 17, mRNA Flu Vaccine VRBPAC Vote June 18 — Here's What Both Mean for 2026–27

FDA approved generic baloxavir June 17; VRBPAC voted on mRNA flu vaccine June 18. The 2025–26 flu season killed 24,000 Americans. Here's what both mean for 2026–27.

FDA Advisory Panel Votes Today on First mRNA Flu Vaccine as MFLUSIVA Phase 3 Results Face Intense Scrutiny

FDA Advisory Panel Votes Today on First mRNA Flu Vaccine as MFLUSIVA Phase 3 Results Face Intense Scrutiny

FDA VRBPAC votes June 18 on Moderna's MFLUSIVA — the first mRNA flu vaccine. Phase 3 showed 26.6% RVE vs. standard dose; 47.9% vs. healthcare outcomes. PDUFA August 5, 2026.

RFK Jr critic Paul Offit removed from FDA vaccine advisory committee

RFK Jr critic Paul Offit removed from FDA vaccine advisory committee

Offit, long-serving vaccine scientist, says he was not given a reason for dismissal after initially being offered extension

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pediatric RSV vaccine trial paused by Moderna amid safety concerns

Five infants required hospitalization, with one needing mechanical ventilation.

The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data

Here's a roundup of top developments in the biotech space over the last 24 hours:

Novavax's COVID-19 Vaccine For Adults Over 18 Backed By FDA Advisors: What's Next?

Novavax, Inc. (NASDAQ: NVAX) announced the U.S.

Novavax Shares Gain Following FDA Advisory Committee's Positive Vote On Emergency Use Authorization (EUA) For COVID-19 Vaccine

Novavax’s (NASDAQ: NVAX) COVID-19 vaccine (NVX-CoV2373) receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC), recommending FDA to grant Emergency Use Authorization (EUA) for individuals aged 18 years and over.

inkl

Read news from The Economist, FT, and more,
with one subscription

FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA

FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA

The FDA has set up June meeting dates to review COVID-19 vaccine submissions, noting that the dates are tentative as none of the submissions are complete. The agency reserved June 8, 21, and 22 for virtual meetings of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)…

FDA approves second shot for 50+

FDA approves second shot for 50+

The authorization for another booster arrives just as BA.2 becomes the dominant strain in the U.S.

1

People

Robert F. Kennedy Jr

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

406,882 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play